Salvatore Ribisi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salvatore Ribisi has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Alba Llop-Guevara
Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
61 shared publications - Alessandro Ferrero
Department of Surgery, Mauriziano Hospital, 10128 Turin, Italy
61 shared publications - Andrea Sartore-Bianchi
Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
61 shared publications - Annalisa Petrelli
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
61 shared publications - Antonino Musolino
Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
61 shared publications - Benedetta Pellegrino
Medical Oncology and Breast Unit, University Hospital of Parma, 43126 Parma, Italy
61 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
MLH1 gene knock-out abrogates responsiveness to olaparib in CAPAN-1 cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
MLH1 gene knock-out abrogates responsiveness to olaparib in CAPAN-1 cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
LOF mutations and clinical characteristics of patients carrying HR gene variants
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
LOF mutations and clinical characteristics of patients carrying HR gene variants
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
HR gene mutations in GEA models used in in vitro and in vivo experiments.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
HR gene mutations in GEA models used in in vitro and in vivo experiments.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
HRD and mutational signature scores in PDXs used in the preclinical trials
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
HRD and mutational signature scores in PDXs used in the preclinical trials
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
BRCA2 LOF mutations in the GEA PDX models used in pre-clinical trials.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
BRCA2 LOF mutations in the GEA PDX models used in pre-clinical trials.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Microsatellite instability (MSI) evaluation in the GTR0264 and GTR0324 tumors.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Microsatellite instability (MSI) evaluation in the GTR0264 and GTR0324 tumors.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
MLH1 KO cells do not display MSI.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
MLH1 KO cells do not display MSI.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
RAD51 assay predicts PARPi response in Gastric Cancer PDX models.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
RAD51 assay predicts PARPi response in Gastric Cancer PDX models.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
A gastric cancer PDX model carrying two LOF mutations in the ATM gene is not responsive to olaparib.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
A gastric cancer PDX model carrying two LOF mutations in the ATM gene is not responsive to olaparib.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Molecular, histological and pathological features of the 57 metastatic gastric cancer patients included in the retrospective analysis
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Molecular, histological and pathological features of the 57 metastatic gastric cancer patients included in the retrospective analysis